Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis

NCT05916365 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
174
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Almirall, S.A.